Poland· PL-100396207
Lutathera
A lutetium (177lu) oxodotreotide product containing lutetii oxodotreotidum [177lu], registered in Poland by Advanced Accelerator Applications. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lutetium (177lu) oxodotreotide is registered in 11 of 19 countries.
Countries holding a registration under ATC V10XX04 (lutetium (177lu) oxodotreotide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Lutetium (177lu) oxodotreotide · ATC V10XX04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Lutetii oxodotreotidum [177Lu]
- Manufacturer
- Advanced Accelerator Applications
- Country
- Poland (PL)
- ATC code
- V10XX04
- ATC class
- Lutetium (177Lu) oxodotreotide
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991350963
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under V10XX04
Lutetium (177lu) oxodotreotide, as other registers publish it.
- NetherlandsEndolucinBeta 40 GBq/mL, radiofarmaceutische precursor, oplossingITM Medical Isotopes GmbH
- PolandLumarkI.D.B. Holland B.V.
- IcelandLutatheraNovartis Europharm Limited
- NorwayLutatheraNovartis Europharm Limited
- DenmarkLutatheraNovartis Europharm Limited
- FinlandLutatheraNovartis Europharm Limited
- CanadaLUTATHERANOVARTIS PHARMACEUTICALS CANADA INC
- CzechiaLUTATHERANovartis Europharm Limited, Dublin
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/400f2cf4-6e98-41a9-a5d4-4561adfbdec9 GET /v1/drugs/400f2cf4-6e98-41a9-a5d4-4561adfbdec9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do infuzji",
"source": "urpl",
"strength": "370 MBq/ml",
"packaging": "05909991350963 ¦ Rpz ¦ EU/1/17/1226/001 ¦ 125101\n1 fiol. 20,5 25 ml\n¦ UR/Z/4b/185/25 - 05909991350963",
"substance": "Lutetium (177Lu) oxodotreotidi 370 MBq/ml",
"common_name": "Lutetii oxodotreotidum [177Lu]",
"pl_product_id": "100396207",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lutetium (177lu) oxodotreotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.